157 related articles for article (PubMed ID: 21540026)
21. Immunohistochemical characterization of endometrial carcinomas: endometrioid, serous and clear cell adenocarcinomas in association with genetic analysis.
Yasuda M
J Obstet Gynaecol Res; 2014 Dec; 40(12):2167-76. PubMed ID: 25363801
[TBL] [Abstract][Full Text] [Related]
22. Microarray analysis reveals distinct gene expression profiles among different histologic types of endometrial cancer.
Risinger JI; Maxwell GL; Chandramouli GV; Jazaeri A; Aprelikova O; Patterson T; Berchuck A; Barrett JC
Cancer Res; 2003 Jan; 63(1):6-11. PubMed ID: 12517768
[TBL] [Abstract][Full Text] [Related]
23. Endometrial carcinoma: controversies in histopathological assessment of grade and tumour cell type.
Clarke BA; Gilks CB
J Clin Pathol; 2010 May; 63(5):410-5. PubMed ID: 20418232
[TBL] [Abstract][Full Text] [Related]
24. Laser capture microdissection with genome-wide expression profiling displayed gene expression signatures in endometrioid endometrial cancer.
Mokhtar NM; Ramzi NH; Yin-Ling W; Rose IM; Hatta Mohd Dali AZ; Jamal R
Cancer Invest; 2012 Feb; 30(2):156-64. PubMed ID: 22122087
[TBL] [Abstract][Full Text] [Related]
25. Differential expression of clusterin according to histological type of endometrial carcinoma.
Ahn HJ; Bae J; Lee S; Ko JE; Yoon S; Kim SJ; Sakuragi N
Gynecol Oncol; 2008 Aug; 110(2):222-9. PubMed ID: 18514801
[TBL] [Abstract][Full Text] [Related]
26. Wilms' tumor gene 1 (WT1) in endometrial carcinoma.
Coosemans A; Moerman P; Verbist G; Maes W; Neven P; Vergote I; Van Gool SW; Amant F
Gynecol Oncol; 2008 Dec; 111(3):502-8. PubMed ID: 18929401
[TBL] [Abstract][Full Text] [Related]
27. [Value of high-field MR diffusion-weighted MR imaging in the diagnosis of endometrial carcinoma].
Wang LX; Zhou CW; Ouyang H
Zhonghua Zhong Liu Za Zhi; 2009 Nov; 31(11):849-53. PubMed ID: 20137351
[TBL] [Abstract][Full Text] [Related]
28. Gene expression profiling of microsatellite unstable and microsatellite stable endometrial cancers indicates distinct pathways of aberrant signaling.
Risinger JI; Maxwell GL; Chandramouli GV; Aprelikova O; Litzi T; Umar A; Berchuck A; Barrett JC
Cancer Res; 2005 Jun; 65(12):5031-7. PubMed ID: 15958545
[TBL] [Abstract][Full Text] [Related]
29. Beta-catenin and E-cadherin expression patterns in high-grade endometrial carcinoma are associated with histological subtype.
Schlosshauer PW; Ellenson LH; Soslow RA
Mod Pathol; 2002 Oct; 15(10):1032-7. PubMed ID: 12379748
[TBL] [Abstract][Full Text] [Related]
30. Mutation of PPP2R1A: a new clue in unveiling the pathogenesis of uterine serous carcinoma.
Shih IeM; Wang TL
J Pathol; 2011 May; 224(1):1-4. PubMed ID: 21432855
[TBL] [Abstract][Full Text] [Related]
31. TP53 Mutational Spectrum in Endometrioid and Serous Endometrial Cancers.
Schultheis AM; Martelotto LG; De Filippo MR; Piscuglio S; Ng CK; Hussein YR; Reis-Filho JS; Soslow RA; Weigelt B
Int J Gynecol Pathol; 2016 Jul; 35(4):289-300. PubMed ID: 26556035
[TBL] [Abstract][Full Text] [Related]
32. [Histologic diagnosis of endometrial cancer].
Kaku T; Kawano Y; Hagiwara T
Nihon Rinsho; 2004 Oct; 62 Suppl 10():309-12. PubMed ID: 15535257
[No Abstract] [Full Text] [Related]
33. Dominant-negative mutation of p53 tumor suppressor gene in endometrial carcinoma.
Sakuragi N; Hirai A; Tada M; Yamada H; Yamamoto R; Fujimoto S; Moriuchi T
Gynecol Oncol; 2001 Dec; 83(3):485-90. PubMed ID: 11733960
[TBL] [Abstract][Full Text] [Related]
34. The expression of the miRNA-200 family in endometrial endometrioid carcinoma.
Lee JW; Park YA; Choi JJ; Lee YY; Kim CJ; Choi C; Kim TJ; Lee NW; Kim BG; Bae DS
Gynecol Oncol; 2011 Jan; 120(1):56-62. PubMed ID: 21035172
[TBL] [Abstract][Full Text] [Related]
35. High-resolution gene copy number and expression profiling of human chromosome 22 in ovarian carcinomas.
Benetkiewicz M; Wang Y; Schaner M; Wang P; Mantripragada KK; Buckley PG; Kristensen G; Børresen-Dale AL; Dumanski JP
Genes Chromosomes Cancer; 2005 Mar; 42(3):228-37. PubMed ID: 15578687
[TBL] [Abstract][Full Text] [Related]
36. microRNA expression profiling of endometrial endometrioid adenocarcinomas and serous adenocarcinomas reveals profiles containing shared, unique and differentiating groups of microRNAs.
Devor EJ; Hovey AM; Goodheart MJ; Ramachandran S; Leslie KK
Oncol Rep; 2011 Oct; 26(4):995-1002. PubMed ID: 21725615
[TBL] [Abstract][Full Text] [Related]
37. Differentially androgen-modulated genes in ovarian epithelial cells from BRCA mutation carriers and control patients predict ovarian cancer survival and disease progression.
Motamed-Khorasani A; Jurisica I; Letarte M; Shaw PA; Parkes RK; Zhang X; Evangelou A; Rosen B; Murphy KJ; Brown TJ
Oncogene; 2007 Jan; 26(2):198-214. PubMed ID: 16832351
[TBL] [Abstract][Full Text] [Related]
38. Use of mutation profiles to refine the classification of endometrial carcinomas.
McConechy MK; Ding J; Cheang MC; Wiegand K; Senz J; Tone A; Yang W; Prentice L; Tse K; Zeng T; McDonald H; Schmidt AP; Mutch DG; McAlpine JN; Hirst M; Shah SP; Lee CH; Goodfellow PJ; Gilks CB; Huntsman DG
J Pathol; 2012 Sep; 228(1):20-30. PubMed ID: 22653804
[TBL] [Abstract][Full Text] [Related]
39. S100A1 expression in ovarian and endometrial endometrioid carcinomas is a prognostic indicator of relapse-free survival.
DeRycke MS; Andersen JD; Harrington KM; Pambuccian SE; Kalloger SE; Boylan KL; Argenta PA; Skubitz AP
Am J Clin Pathol; 2009 Dec; 132(6):846-56. PubMed ID: 19926575
[TBL] [Abstract][Full Text] [Related]
40. Histologic type, organ of origin, and Wnt pathway status: effect on gene expression in ovarian and uterine carcinomas.
Shedden KA; Kshirsagar MP; Schwartz DR; Wu R; Yu H; Misek DE; Hanash S; Katabuchi H; Ellenson LH; Fearon ER; Cho KR
Clin Cancer Res; 2005 Mar; 11(6):2123-31. PubMed ID: 15788657
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
